ClinVar Miner

Submissions for variant NM_002834.5(PTPN11):c.853T>G (p.Phe285Val)

dbSNP: rs397507531
Minimum review status: Collection method:
Minimum conflict level:
ClinVar version:
Total submissions: 7
Download table as spreadsheet
Submitter RCV SCV Clinical significance Condition Last evaluated Review status Method Comment
Center for Genomics, Ann and Robert H. Lurie Children's Hospital of Chicago RCV001027842 SCV001190462 likely pathogenic Noonan syndrome 1; Metachondromatosis; LEOPARD syndrome 1 2019-10-24 criteria provided, single submitter clinical testing PTPN11 NM_002834.4 exon 7 p.Phe285Val (c.853T>G): This variant has not been reported in the literature and is not present in large control databases. Evolutionary conservation and computational predictive tools suggest that this variant may impact the protein. Additionally, other variants at the same amino acid residue (Phe285Cys, Phe285Ile, Phe285Leu, Phe285Ser) have also been reported in association with disease, further supporting that this region has significance (Tartilglia 2002 PMID:11992261, Tartiglia 2006 PMID:16358218, Ferrero 2008 PMID:18678287, Hakami 2016 PMID:26918529). In summary, data on this variant is highly suspicious for disease, but requires further evidence for pathogenicity. Therefore, this variant is classified as likely pathogenic.
Al Jalila Children’s Genomics Center, Al Jalila Childrens Speciality Hospital RCV004593977 SCV002818247 likely pathogenic Noonan syndrome 1 2024-10-04 criteria provided, single submitter research PM2, PM5_Strong, PP3, PP4
Revvity Omics, Revvity RCV002508779 SCV003818014 uncertain significance not provided 2019-03-22 criteria provided, single submitter clinical testing
Center for Genomics, Ann and Robert H. Lurie Children's Hospital of Chicago RCV003224796 SCV003920891 likely pathogenic Noonan syndrome 1; Juvenile myelomonocytic leukemia; Metachondromatosis; LEOPARD syndrome 1 criteria provided, single submitter clinical testing PTPN11 NM_002834.4 exon 7 p.Phe285Val (c.853T>G): This variant has not been reported in the literature and is not present in large control databases. Evolutionary conservation and computational predictive tools suggest that this variant may impact the protein. Additionally, other variants at the same amino acid residue (Phe285Cys, Phe285Ile, Phe285Leu, Phe285Ser) have also been reported in association with disease, further supporting that this region has significance (Tartilglia 2002 PMID:11992261, Tartiglia 2006 PMID:16358218, Ferrero 2008 PMID:18678287, Hakami 2016 PMID:26918529). In summary, data on this variant is highly suspicious for disease, but requires further evidence for pathogenicity. Therefore, this variant is classified as likely pathogenic.
PreventionGenetics, part of Exact Sciences RCV004532489 SCV004113322 likely pathogenic PTPN11-related disorder 2023-05-31 criteria provided, single submitter clinical testing The PTPN11 c.853T>G variant is predicted to result in the amino acid substitution p.Phe285Val. To our knowledge, this variant has not been reported in the literature or in a large population database (http://gnomad.broadinstitute.org), indicating this variant is rare. This variant has conflicting interpretations of pathogenicity in ClinVar of likely pathogenic and uncertain (https://www.ncbi.nlm.nih.gov/clinvar/variation/40527/). Alternate missense variants affecting this residue (p.Phe285Ile, p.Phe285Leu, p.Phe285Ser, p.Phe285Cys) have been reported as pathogenic (Tartaglia et al. 2002. PubMed ID: 11992261; Tartaglia et al. 2006. PubMed ID: 16358218; Hung et al. 2007. PubMed ID: 17339163; Ferrero et al. 2008. PubMed ID: 18678287). This variant is interpreted as likely pathogenic.
Labcorp Genetics (formerly Invitae), Labcorp RCV003539766 SCV004282398 uncertain significance RASopathy 2023-03-13 criteria provided, single submitter clinical testing This sequence change replaces phenylalanine, which is neutral and non-polar, with valine, which is neutral and non-polar, at codon 285 of the PTPN11 protein (p.Phe285Val). This variant is not present in population databases (gnomAD no frequency). This variant has not been reported in the literature in individuals affected with PTPN11-related conditions. ClinVar contains an entry for this variant (Variation ID: 40527). An algorithm developed to predict the effect of missense changes on protein structure and function (PolyPhen-2) suggests that this variant  is likely to be tolerated. This variant disrupts the p.Phe285 amino acid residue in PTPN11. Other variant(s) that disrupt this residue have been determined to be pathogenic (PMID: 11992261, 15689434, 15996221, 23771920). This suggests that this residue is clinically significant, and that variants that disrupt this residue are likely to be disease-causing. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance.
Victorian Clinical Genetics Services, Murdoch Childrens Research Institute RCV004593977 SCV005086429 pathogenic Noonan syndrome 1 2023-07-17 criteria provided, single submitter clinical testing Based on the classification scheme VCGS_Germline_v1.3.4, this variant is classified as Pathogenic. Following criteria are met: 0103 - Both loss of function and gain of function are known mechanisms of disease for this gene. Metachondromatosis (MIM#156250) and Noonan syndrome with multiple lentigines have been associated with loss of function variants, whereas Noonan syndrome 1 (MIM#163950) is caused by gain of function variants (PMIDs: 11992261, 24935154, 21533187; ClinGen expert panel). (I) 0107 - This gene is associated with autosomal dominant disease. (I) 0115 - Variants in this gene are known to have variable expressivity. Noonan syndrome is known to have variable expressivity (PMID: 20301303). (I) 0200 - Variant is predicted to result in a missense amino acid change from phenylalanine to valine. (I) 0251 - This variant is heterozygous. (I) 0301 - Variant is absent from gnomAD (both v2 and v3). (SP) 0501 - Missense variant consistently predicted to be damaging by multiple in silico tools or highly conserved with a major amino acid change. (SP) 0602 - Variant is located in a hotspot region or cluster of pathogenic variants (DECIPHER). (SP) 0701 - Other missense variants comparable to the one identified in this case have very strong previous evidence for pathogenicity. Alternative changes at this residue to Leu, Tyr, Cys, Ile, and Ser haven been classified as pathogenic or likely pathogenic by multiple clinical laboratories in ClinVar. (SP) 0802 - This variant has moderate previous evidence of pathogenicity in unrelated individuals. This variant has been classified as a VUS and as likely pathogenic by clinical laboratories in ClinVar, and has been reported in the literature in two individuals with Noonan syndrome (PMID: 31164752). (SP) 0905 - No published segregation evidence has been identified for this variant. (I) 1007 - No published functional evidence has been identified for this variant. (I) 1203 - This variant has been shown to be de novo in the proband (parental status confirmed) (by trio analysis). (SP) Legend: (SP) - Supporting pathogenic, (I) - Information, (SB) - Supporting benign

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. Neither the University of Utah nor the National Institutes of Health independently verfies the submitted information. If you have questions about the information contained on this website, please see a health care professional.